MX2012003411A - Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina. - Google Patents

Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina.

Info

Publication number
MX2012003411A
MX2012003411A MX2012003411A MX2012003411A MX2012003411A MX 2012003411 A MX2012003411 A MX 2012003411A MX 2012003411 A MX2012003411 A MX 2012003411A MX 2012003411 A MX2012003411 A MX 2012003411A MX 2012003411 A MX2012003411 A MX 2012003411A
Authority
MX
Mexico
Prior art keywords
ceftaroline
compositions
methods
bacterial infections
treating bacterial
Prior art date
Application number
MX2012003411A
Other languages
English (en)
Inventor
Dirk Thye
George Talbot
Original Assignee
Forest Lab Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43757152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012003411(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Forest Lab Holdings Ltd filed Critical Forest Lab Holdings Ltd
Publication of MX2012003411A publication Critical patent/MX2012003411A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

La presente invención se refiere a composiciones que comprenden ceftarolina o un profármaco de la misma (por ejemplo, fosamil de ceftarolina), y a métodos para tratar infecciones bacterianas, tales como infecciones de la estructura y piel complicadas (cSSSI) y pneumonía bacteriana adquirida en (a comunidad (CABP), mediante la administración de ceftarolina o un profármaco de la misma, (por ejemplo, fosamil de ceftarolina).
MX2012003411A 2009-09-21 2010-09-21 Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina. MX2012003411A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24412009P 2009-09-21 2009-09-21
US29490110P 2010-01-14 2010-01-14
PCT/US2010/049659 WO2011035305A1 (en) 2009-09-21 2010-09-21 Compositions and methods for treating bacterial infections using ceftaroline

Publications (1)

Publication Number Publication Date
MX2012003411A true MX2012003411A (es) 2012-04-30

Family

ID=43757152

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012003411A MX2012003411A (es) 2009-09-21 2010-09-21 Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina.
MX2012003201A MX2012003201A (es) 2009-09-21 2010-09-21 Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012003201A MX2012003201A (es) 2009-09-21 2010-09-21 Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina.

Country Status (23)

Country Link
US (2) US20110071114A1 (es)
EP (1) EP2480236A4 (es)
KR (1) KR20120083344A (es)
CN (1) CN102781451A (es)
AU (1) AU2010295269B2 (es)
BR (1) BR112012006250B1 (es)
CA (1) CA2774772A1 (es)
CL (1) CL2012000694A1 (es)
CO (1) CO6531417A2 (es)
CR (1) CR20120137A (es)
CU (1) CU20120048A7 (es)
DO (1) DOP2012000077A (es)
EA (1) EA029149B1 (es)
EC (1) ECSP12011739A (es)
GT (1) GT201200082A (es)
HN (1) HN2012000585A (es)
IL (1) IL218349A0 (es)
MX (2) MX2012003411A (es)
NI (1) NI201200045A (es)
PE (2) PE20121819A1 (es)
SG (1) SG178936A1 (es)
WO (1) WO2011035305A1 (es)
ZA (1) ZA201202924B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
AU2012270051B2 (en) 2011-06-17 2016-12-22 Pfizer Anti-Infectives Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
CN107621512B (zh) * 2017-11-02 2020-07-31 扬子江药业集团有限公司 一种柱前衍生化法测定头孢洛林酯侧链酰氯纯度的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW473479B (en) * 1997-12-19 2002-01-21 Takeda Chemical Industries Ltd Phosphonocephem derivatives, their production and use
EP2020416A1 (en) * 2000-08-10 2009-02-04 Takeda Pharmaceutical Company Limited Phosphonocephem compound
WO2002093162A2 (en) * 2001-05-17 2002-11-21 Mcgill University Individualization of therapy with antibiotic agents
JP4625637B2 (ja) * 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US20090082326A1 (en) * 2007-09-21 2009-03-26 Forest Laboratories Holdings Limited Soluble dosage forms containing cephem derivatives suitable for parenteral administration

Also Published As

Publication number Publication date
EP2480236A1 (en) 2012-08-01
BR112012006250B1 (pt) 2021-07-06
EA201200501A1 (ru) 2012-10-30
ECSP12011739A (es) 2012-05-30
IL218349A0 (en) 2012-04-30
CA2774772A1 (en) 2011-03-24
WO2011035305A1 (en) 2011-03-24
ZA201202924B (en) 2012-12-27
CN102781451A (zh) 2012-11-14
EP2480236A4 (en) 2013-04-17
EA029149B1 (ru) 2018-02-28
CL2012000694A1 (es) 2012-08-31
NI201200045A (es) 2012-11-02
US20150258126A1 (en) 2015-09-17
KR20120083344A (ko) 2012-07-25
MX2012003201A (es) 2012-05-08
US20110071114A1 (en) 2011-03-24
SG178936A1 (en) 2012-04-27
BR112012006250A2 (pt) 2016-05-31
DOP2012000077A (es) 2012-05-31
US9629861B2 (en) 2017-04-25
CO6531417A2 (es) 2012-09-28
HN2012000585A (es) 2015-06-15
AU2010295269B2 (en) 2014-06-05
AU2010295269A1 (en) 2012-04-12
PE20171176A1 (es) 2017-08-22
CU20120048A7 (es) 2012-10-15
CR20120137A (es) 2012-05-28
PE20121819A1 (es) 2013-02-01
GT201200082A (es) 2014-12-22

Similar Documents

Publication Publication Date Title
JOP20180102B1 (ar) مركب صيدلاني
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
GB0917002D0 (en) Improved shigella blebs
PH12013502192A1 (en) Antibodies against human angiopoietin 2
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
MX2012001156A (es) Moleculas que contienen boro trisustituidas.
MX346665B (es) Composiciones pesticidas y procedimientos relacionados con estas.
EA201001639A1 (ru) Композиции и способы их получения и применения
PH12015501609A1 (en) Phenicol antibacterials
NZ602544A (en) Crystalline forms of a macrolide, and uses therefor
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
GB2518813A (en) OMV vaccine against Burkholderia infections
MX2011006803A (es) Agentes antibacterianos novedosos para el tratamiento de infecciones gram positivas.
UA111210C2 (uk) Антибактеріальні 3,4-дигідро-1h-[1,8]нафтиридинони, заміщені циклопента[c]піролом
SG10201900541QA (en) Derivatives of xanthone compounds
WO2013166282A3 (en) Methods and compositions for treating bacterial infection
ZA201008160B (en) Compositions for the treatment of hair loss
SG178936A1 (en) Compositions and methods for treating bacterial infections using ceftaroline
MX2009009074A (es) Macrolidos basados en eritromicina.
WO2012082942A3 (en) Neuropeptide analogs, compositions, and methods for treating pain
MX337145B (es) Composiciones farmaceuticas.
MX2014004742A (es) Nuevos agentes antibacterianos de fenicol.
TN2010000463A1 (en) Compositions and methods for preparing and using same
MY182136A (en) Pharmaceutical compositions
TN2010000583A1 (en) Organic compounds